Cite
Cotreau MM, Hale CL, Jacobson L, et al. Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study. Clin Pharmacol Drug Dev. 2012;1(3):102-9doi: 10.1177/2160763X12447303.
Cotreau, M. M., Hale, C. L., Jacobson, L., Oelke, C. S., Strahs, A. L., Kochan, R. G., Sanga, M., Slichenmyer, W., & Vargo, D. L. (2012). Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study. Clinical pharmacology in drug development, 1(3), 102-9. https://doi.org/10.1177/2160763X12447303
Cotreau, Monette M, et al. "Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study." Clinical pharmacology in drug development vol. 1,3 (2012): 102-9. doi: https://doi.org/10.1177/2160763X12447303
Cotreau MM, Hale CL, Jacobson L, Oelke CS, Strahs AL, Kochan RG, Sanga M, Slichenmyer W, Vargo DL. Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study. Clin Pharmacol Drug Dev. 2012 Jul;1(3):102-9. doi: 10.1177/2160763X12447303. PMID: 27121337.
Copy
Download .nbib